Investor Relations

IR Home

Stock Chart
VNDA (Common)
ExchangeNASDAQ (US Dollar)
Price$10.27
Change (%) Stock is Up 0.01 (0.10%)
Volume570,258
Data as of 05/22/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients... More >>

May 2015?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-5-4-3-2-112
345
05/05/15
8-K
Formats:  Excel HTML Adobe PDF Word
67
05/07/15
10-Q
Formats:  Excel HTML Adobe PDF Word XBRL
89
10111213141516
1718
05/18/15
3
Formats:  Excel HTML Adobe PDF Word
1920212223
24252627282930
31515253545556

Primary IR Contact

For members of the press or investor community who wish to obtain more information about Vanda, please contact
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals, Inc.
(202) 734-3428

Recent News
05/11/15
Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
05/06/15
Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results
04/24/15
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union
More >>
Upcoming Events
There are currently no events scheduled.
More >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
  
Home | About Vanda | Product Pipeline | 24 | Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2007 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy